Sweden's SenzaGen Q2 revenue rises, core loss narrows
Sweden's SenzaGen Q2 revenue rises, core loss narrows
Overview
Sweden non-animal testing firm's Q2 revenue rose 13% yr/yr to SEK 15.3 mln
Q2 EBITDA loss narrowed to SEK -1.2 mln from SEK -3.9 mln a year earlier
Company reported positive cash flow from operating activities and increased order intake at VitroScreen
Outlook
Company did not provide specific financial guidance for future quarters or the full year in the press release
Result Drivers
POSITIVE OPERATING CASH FLOW - Co reported positive cash flow from operating activities during the quarter
Company press release: ID:nMFN4mKt8x
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EBITDA |
| -SEK 1.2 mln |
|
Reuters Recommended Reads
Aug 20 - Sweden's SenzaGen Q2 revenue rises 13% on VitroScreen turnaround
Aug 20 - Sweden's Ascelia Pharma Q2 operating loss narrows
Aug 20 - Sweden's Medivir Q2 turnover falls
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)